Oncternal Therapeutics (NASDAQ:ONCT) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated a neutral rating and issued a $1.30 target price on shares of Oncternal […]
More Stories
Assenagon Asset Management S.A. Has $3.79 Million Stock Holdings in American Tower Co. (NYSE:AMT)
Assenagon Asset Management S.A. lifted its stake in American Tower Co. (NYSE:AMT – Free Report) by 1.9% in the first...
CVA Family Office LLC Sells 113 Shares of Genuine Parts (NYSE:GPC)
CVA Family Office LLC lessened its holdings in Genuine Parts (NYSE:GPC – Free Report) by 30.2% during the 1st quarter,...
CVA Family Office LLC Acquires 46 Shares of AppLovin Co. (NASDAQ:APP)
CVA Family Office LLC grew its holdings in AppLovin Co. (NASDAQ:APP – Free Report) by 53.5% in the 1st quarter,...
CVA Family Office LLC Trims Position in Global Payments Inc. (NYSE:GPN)
CVA Family Office LLC cut its stake in shares of Global Payments Inc. (NYSE:GPN – Free Report) by 50.6% during...
Howmet Aerospace Inc. (NYSE:HWM) Shares Acquired by CVA Family Office LLC
CVA Family Office LLC increased its holdings in Howmet Aerospace Inc. (NYSE:HWM – Free Report) by 15.7% during the first...
CVA Family Office LLC Decreases Position in Eversource Energy (NYSE:ES)
CVA Family Office LLC lowered its stake in shares of Eversource Energy (NYSE:ES – Free Report) by 12.1% in the...